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Viruses can escape cytotoxic T cell (CTL) immunity
by avoiding presentation of viral components via
endogenous MHC class I antigen presentation in
infected cells. Cross-priming of viral antigens cir-
cumvents such immune escape by allowing non-
infected dendritic cells to activate virus-specific
CTLs, but they remain ineffective against infected
cells in which immune escape is functional. Here,
we show that cross-presentation of antigen released
from adenovirus-infected hepatocytes by liver
sinusoidal endothelial cells stimulated cross-primed
effector CTLs to release tumor necrosis factor (TNF),
which killed virus-infected hepatocytes through
caspase activation. TNF receptor signaling specifi-
cally eliminated infected hepatocytes that showed
impaired anti-apoptotic defense. Thus, CTL immune
surveillance against infection relies on two similarly
important but distinct effector functions that are
both MHC restricted, requiring either direct antigen
recognition on target cells and canonical CTL
effector function or cross-presentation and a nonca-
nonical effector function mediated by TNF.
INTRODUCTION
Viruses have developed strategies to escape virus-specific
immunity. Among these, impairment of the classical endogenous
MHC class I antigen-presentation pathway allows the virus
to escape recognition by virus-specific effector CD8 T cells
(CTLs) that normally would destroy infected cells (Reddehase,478 Cell Reports 2, 478–487, September 27, 2012 ª2012 The Author2002). Antigen cross-presentation, which is a hallmark of profes-
sional antigen-presenting cells (APCs) such as dendritic cells
(DCs), allows presentation of endocytosed antigen on MHC
class I molecules to CTLs (Kurts et al., 2010) and is usually not
affected by such viral escape strategies (Sigal et al., 1999).
Hence, this viral escape mechanism is not operational in nonin-
fected DCs, allowing them to cross-present antigens captured
from infected cells to naive CTLs. Thereby, cross-priming DCs
initiate virus-specific CTL immunity regardless of viral immune
escape in infected cells (Allan et al., 2003). To this end, DCs
must be licensed by CD4 helper T cells or by NKT cells to
cross-prime CTLs efficiently (Schoenberger et al., 1998; Semm-
ling et al., 2010). Also, type I interferon (IFN), which is expressed
and released from virus-infected cells, has antiviral effects and
can stimulate cross-presentation (Le Bon et al., 2003). Taken
together, cross-priming of viral antigens by appropriately
licensed DCs is an important step in antiviral immunity, which
establishes large numbers of virus-specific CTLs to combat
infection at peripheral sites (Kurts et al., 2010).
However, already cross-primed CTLs still have to recognize
viral antigens on infected cells in peripheral organs in order to
attack them, and viral escape from MHC class I presentation in
virus-infected cells obviously impedes this critical step of T cell
immunity (Holtappels et al., 2004). Moreover, infection of solid
organs like the liver by viruses such as hepatitis B or C or
lymphocytic choriomeningitis virus (LCMV) is believed to require
direct interaction of virus-specific CTLswith virus-infected hepa-
tocytes to control infection (Guidotti and Chisari, 2001; Reher-
mann and Nascimbeni, 2005), which may require additional
time to recruit significant numbers of CTLs from the circulation
into infected parenchymal tissue. It is unresolved how cross-
primed CTLs can perform effector functions under conditions
of viral immune escape in infected cells because it is believed
that direct MHC class I-restricted antigen recognition ons
virus-infected cells is required for CTL-mediated elimination.
Here, we identify a noncanonical CTL effector mechanism that
overcomes these limitations.
RESULTS
Cross-Presentation by Liver Endothelial Cells Triggers
CTL Effector Function
We investigated the relevance of endogenous antigen presenta-
tion versus cross-presentation within a virus-infected organ for
CTL effector function. We used an experimental viral hepatitis
model where mice were infected with recombinant hepatotropic
adenoviruses (AdOVA), which led to preferential infection and
expressionofOvalbumin inhepatocytes (FigureS1A). Then, these
mice received in vitro-activated OVA-specific H-2Kb-restricted
CTLs (OT-I cells) by adoptive transfer, which readily exert
effector function upon antigen recognition. As recipients, we
used transgenic mice with cell-type-specific expression of MHC
class I (H-2Kb) in order to identify the cell on which antigen must
be recognized by specific CTLs to elicit immune surveillance.
Adoptive transfer of in vitro-activated OVA-specific CTLs into
AdOVA-infected wild-type mice rapidly caused liver damage
within 48 hr as measured by elevation in serum liver enzymes
(serum ALT [sALT]) (Figure 1A), consistent with the key role of
CTLs for viral hepatitis (Ando et al., 1993; Maini et al., 2000).
To study the relevance of direct MHC I-restricted recognition
of infected hepatocytes by CTLs, we used transgenic mice
with hepatocyte-restricted MHC class I expression (CRP-Kb).
In these mice we found unexpectedly reduced CTL-mediated
hepatitis compared to mice with ubiquitous H-2Kb expression
(Figure 1A), indicating that CTLs recognized not only infected
hepatocytes but also other APCs. To further investigate the rele-
vance of antigen cross-presentation by nonhepatocytes, we
used a transgenic mouse where H-2Kb expression under tie2
promoter drives expression in endothelial cells and some bone
marrow-derived immune cells (Limmer et al., 2005). Because
liver sinusoidal endothelial cells (LSECs) are as competent in
cross-presentation as DCs (Limmer et al., 2000; Schurich
et al., 2009), we investigated their contribution by targeting these
tissue-resident cells with transgenic tie2-Kb mice. CTL transfer
into virus-infected tie2-Kb mice caused hepatitis similar to
H-2b mice with ubiquitous H-2Kb expression (Figure 1A), which
is consistent with cross-presentation of hepatocyte-derived
antigens by LSECs. The importance of cross-presenting LSECs
for CTL-mediated viral hepatitis was substantiated by the prom-
inent lymphocyte accumulation in tie2-Kb—similar to H-2b mice
(Figure 1B). We excluded a role for bone marrow-derived
APCs by using [DBA/2- > tie2-Kb] chimeric mice where only
organ-resident LSECs but not macrophages or DCs expressed
H-2Kb, which sufficed for induction of viral hepatitis (Figure 1C).
There was no contribution from bone marrow-derived immune
cells to CTL-mediated viral hepatitis in [tie2-Kb- > DBA/2]
chimeric mice (Figure 1C). A contribution from macrophages
was further excluded because clodronate-induced depletion
did not significantly alter CTL-mediated viral hepatitis (Fig-
ure S1B), which is distinct from the direct pathogenetic role of
Kupffer cells in viral hepatitis when naive CTLs are transferred
(Giannandrea et al., 2009). It is important to note that in tie2-KbCelmice, virus-infected hepatocytes did not express H-2Kb and
thus did not present antigen to CTLs at all. We conclude that
local cross-presentation by LSECs contributed to CTL-induced
viral hepatitis.
We confirmed the relevance of these findings by repeating the
experiments with OVA-specific CTLs that were primed during
a viral infection in vivo. Their transfer also elicited liver damage
if they recognized their antigen on cross-presenting LSECs
in vivo (Figure S1C). Antibody-mediated depletion studies
revealed that NK cells were not involved in hepatitis (Figure S1D)
and that no antiviral T cell immunity from the endogenous T cell
repertoire was observedwithin the time frame of the experiments
(Figure S1E).
We next validated LSEC cross-presentation of hepatocyte-
derived viral antigens to CTLs. LSECs isolated from AdOVA-
infected tie2-Kb mice but not from AdGFP-infected mice
stimulated OVA-specific CTLs directly ex vivo (Figure 1D). We
excluded transfer of peptide-loaded MHC class I molecules
from hepatocytes to LSECs because LSECs isolated from
CRP-Kb mice that did not express H-2Kb on endothelial cells
(Figure S1F) also did not stimulate CTLs ex vivo (Figure 1D). Simi-
larly, CTLs killed hepatocytes isolated from CRP-Kb but not from
tie2-Kb mice in vitro (Figure S1G). LSECs cross-presented
in vitro OVA that was released fromAdOVA-infected HepG2 cells
(Figure 1E). LSECswere not infected by AdOVA, excluding direct
antigen presentation by this cell population (Figure 1E). Taken
together, LSECs cross-presented hepatocyte-derived antigens
to CTLs and thereby triggered viral hepatitis even in the
absence of MHC class I-restricted CTL recognition of virus-
infected hepatocytes, which may serve to counteract viral
immune escape of MHC class I-restricted antigen presentation
in infected hepatocytes.
Next, we examined the relevance of CTL recognition by cross-
presenting cells for antiviral immunity. The ability of CTLs to elim-
inate virus-infected hepatocytes even in the absence of MHC
I-restricted target cell recognition was shown by reduction in
the numbers of virus-infected hepatocytes in tie2-Kb mice (Fig-
ure 1F). Furthermore, we employed a highly sensitive method
for detection of antiviral CTL effector function in the liver, which
is based on quantitative in vivo bioluminescence imaging of
virus-encoded luciferase (Stabenow et al., 2010). Following
adoptive transfer, CTLs significantly controlled viral gene
expression in infected hepatocytes demonstrated by reduced
bioluminescence in the livers of virus-infected tie2-Kb mice,
whereas CTLs in CRP-Kb mice required 48 hr to achieve similar
antiviral effects (Figure 1G). This indicated that local cross-
presentation of hepatocyte-derived antigens to CTLs allowed
for rapid control of viral infection and may synergize with direct
antigen presentation by infected hepatocytes at later time
points, as illustrated in Figure 1H.
CTL-Derived TNF Causes Liver Damage after Viral
Infection
Given the independence of CTL-induced liver damage from
MHC class I-restricted antigen recognition on virus-infected
hepatocytes, we wondered what had triggered hepatocyte
death after CTL activation by cross-presenting LSECs. Whereas
cross-presentation by LSECs to naive CTLs results inl Reports 2, 478–487, September 27, 2012 ª2012 The Authors 479
Figure 1. Cross-Presentation by LSECs Triggers a Noncanonical CTL Effector Function
(A) H-2b or transgenic mice with hepatocyte (CRP-Kb) or endothelial cell (tie2-Kb)-restricted H-2Kb expression were infected i.v. with recombinant AdGFP or
AdOVA (23 108 pfu/mouse) and 2 days later received in vitro-activated OVA-specific OT-I effector CTLs by adoptive transfer (107/mouse). After further 2 days,
sALT was determined (n = 4 mice per group; three separate experiments). ns, nonsignificant (p = 0.2979); **, significant (p = 0.0028).
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development of T cell nonresponsiveness leaving LSECs intact
(Diehl et al., 2008; Limmer et al., 2000), we observed killing of
LSECs in vitro and in vivo after cross-presentation to CTLs that
had been activated 4 days before by DCs (Figures 2A and
S2A). This may damage the sinusoidal endothelial layer in the
liver. Endothelial lesions are known to elicit platelet activation
(Wu and Thiagarajan, 1996). Although we observed platelet
accumulation at sites of viral infection in the liver (Figure 2B),
platelet depletion by antibodies (Figure S2B) did not attenuate
CTL-induced hepatitis (Figure 2C). This excluded platelet-medi-
ated microvascular thrombosis as the cause of liver damage in
our experimental setting. Notwithstanding, platelets become
activated in the context of viral infection of the liver, alter the
hepatic microcirculation, and can worsen viral hepatitis (Ianna-
cone et al., 2005; Lang et al., 2008). How then could CTLs exert
cytotoxicity in the absence of MHC class I-restricted antigen
recognition on infected hepatocytes?
We reasoned that cytokines might play a role, and first exam-
ined IFNg and IFNa/b, two obvious candidates with potent anti-
viral activity (Guidotti and Chisari, 2001). However, hepatitis was
not attenuated in virus-infected IFNgR/ or IFNa/bR/ mice
(Figure 2D). In contrast, CTL-mediated viral hepatitis was signif-
icantly reduced in TNFR/ mice, revealing a crucial role for
tumor necrosis factor (TNF) (Figure 2D), which is involved in non-
cytopathic antiviral defense (Guidotti and Chisari, 2001). By
intracellular flow cytometry we found that antigen-presenting
LSECs induced strong TNF expression in CTLs (Figures S2C
and S2D), arguing for a role of CTL-derived TNF in viral hepatitis.
Transfer of TNF-competent CTLs into virus-infected TNF/
mice elicited liver damage, confirming that CTL-produced TNF
sufficed for inducing viral hepatitis (Figure 2E). Moreover,
transfer of TNF/ CTLs into TNF-competent virus-infected
mice led to a 40% reduction in liver damage, indicating that
TNF accounted for a significant part of the CTL effector function
against virus-infected hepatocytes (Figure 2F). Taken together,
these results define a CTL effector function that depends on
stimulation by cross-presenting cells, is independent of direct
MHC class I-restricted target cell recognition and, therefore, of
viral immune escape from antigen presentation, and relies on
CTL-derived TNF as effector molecule.
Viral Infection Sensitizes Hepatocytes for TNF-Induced
Cell Death
If CTLs employed TNF to kill hepatocytes, the question arises
whether such killingwas restricted to infected cells.We therefore(B) Mice were treated as in (A). Histopathological analysis (H&E) of liver sections t
lymphocytes. Scale bars, 100 mm.
(C) Bone marrow chimeric mice were generated as indicated. Adenoviral infectio
described in (A). *, significant (p = 0.0242).
(D) Mice were infected as in (A), LSECs were isolated from H-2b, CRP-Kb, or tie2
measuring IL-2 release from B3Z cells.
(E) LSECs and/or HepG2 cells were infected in vitro with AdOVA or AdGFP, and
(F) Enumeration of virally infected hepatocytes by immunohistochemistry of mice
(G) Bioluminescence from H-2k (devoid of H-2Kb, as negative control), tie2-Kb, or
luciferase as fusion protein and CTL transfer (n = 4 mice per group). *p = 0.0114
(H) Scheme for CTL-mediated liver damage in absence of direct MHC I-restricte
(C and D) One out of three independent experiments is shown.
See also Figure S1.
Celstudied the situation in which LSECs cross-presented OVA in the
absence of viral infection of hepatocytes by injecting soluble
OVA, which is rapidly and efficiently cross-presented by LSECs
(Schurich et al., 2009), followed by CTL transfer. There was no
hepatitis even after providing additional TNF by intravenous
(i.v.) injection (Figure 3A), demonstrating that CTL activation
and release of TNF are required for viral hepatitis but are not
sufficient to induce liver damage in noninfected mice.
This suggested that additional factors associated with viral
infection rendered hepatocytes susceptible for TNF-mediated
cell death. In a reductionist’s approach we show that TNF injec-
tion alone independent of other CTL-associated death-inducing
molecules leads to hepatitis in virus-infected mice (Figure 3B).
There was no difference in levels of TNF receptor (TNFR) ex-
pression in infected versus noninfected hepatocytes (Fig-
ure S3A), which excluded a direct effect of infection at the level
of TNF sensing. TNF-induced hepatitis was independent of
OVA expression and also occurred after infection with AdGFP
or AdLacZ (data not shown), demonstrating that sensitivity of
infected hepatocyte to TNF was not a specific feature of OVA
expression. Injection ofUV-inactivated adenovirus did not suffice
to elicit liver damage by TNF (Figure 3B), suggesting that immune
recognition of viral structural patterns did not cause hepatocyte
sensitization. We directly characterized the role of innate recep-
tors involved in recognition of adenoviral infection and liver
damage (Zhu et al., 2007) by injecting animals with synthetic
ligands to these receptors followed by TNF challenge. None of
these ligands rendered hepatocytes susceptible to death by
TNF (Figure 3C). Therewas also no role for inflammasome activa-
tion because the severity of hepatitis after viral infection and TNF
challenge was similar in ASC1/ mice compared to wild-type
mice or after inhibition of caspase-1 (data not shown).
If cell-autonomous mechanisms predisposed infected hepa-
tocytes to TNF killing, then the numbers of infected hepatocytes
should directly correlate with liver damage. Indeed, higher in-
fectious doses of adenoviruses led to increasing sALT levels in
mice treated with the same concentration of TNF (Figure 3D).
Following infection with high-dose adenovirus (109 pfu/mouse),
liver histology and sALT elevation revealed development of
severe liver damage peaking within 4 hr after challenge with
TNF (Figures 3E and 3F). There was a decline of sALT 4 hr after
TNF challenge (Figure S3B), indicating that a single TNF injection
did not suffice to elicit long-lasting liver damage. The synergy of
viral infection and TNF for hepatocyte death was not restricted to
infection with replication-incompetent DNA virus but was alsoaken 2 days after CTL transfer. Arrows indicate accumulation and infiltration of
n and OT-I CTL transfer followed by determination of sALT were performed as
-Kb mice 2 days later, and OVA cross-presentation was determined ex vivo by
cross-presentation to B3Z cells was determined.
treated as in (A). ***, H2d versus Tie2-Kb p = 0.0002; all others p < 0.0001.
CRP-Kb mice after infection with recombinant adenovirus expressing OVA and
for tie2-Kb versus CRP-Kb on day 3.
d target cell recognition.
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Figure 2. CTL-Derived TNF Causes Liver Damage
(A) Incubation of cross-presenting LSECs with increasing numbers of specific CTLs in vitro for 3 hr. Scale bar, 100 mm.
(B–F) Mice were infected with AdGFP or AdOVA (23 108 pfu/mouse), 2 days later adoptive CTL transfer (107/mouse). (B) Visualization of sinusoidal endothelium
by uptake of Alexa 647-labeled BSA; platelet staining with DyLight 488-labeled aGPIb antibody (arrows) in the vicinity of AdGFP-infected hepatocytes
(arrowheads). Confocal laser-scanning microscopy of liver sections 24 hr after CTL transfer. (C) Platelet depletion with aCD42b antibody (4 mg/kg) compared to
isotype control antibody (nondepleted). sALT determination 2 days after CTL transfer (n = 4 mice per group; one of two representative experiments is shown). ns,
nonsignificant (p = 0.1306). (D) sALT determination 2 days after adoptive CTL transfer into the indicated virus-infected knockout mice (n = 3mice per group). Wild-
type versus IFNgR/ nonsignificant (p = 0.8176), wildtype versus IFNAR/ nonsignificant (p = 0.4766), wildtype versus TNFR/ ***, significant (p = 0.0001).
(E and F) Adenoviral infection of wild-type or TNF/mice; sALT determination 2 days after transfer of TNF-competent or TNF/CTLs. *, significant (p = 0.0407).
See also Figure S2.observed after infection with the replication-competent RNA
virus LCMV (Figure 3G). TNF application reduced viremia in
LCMV-infected animals (Figure 3H), demonstrating that TNF
contributed to control of viral infection. These results identified482 Cell Reports 2, 478–487, September 27, 2012 ª2012 The Authora nonredundant combinatorial effect of viral infection and TNF
in killing of infected hepatocytes. We further wondered whether
preexistent inflammation would alter the outcome of TNF-
induced liver damage in virus-infected mice. PolyIC-induceds
Figure 3. Viral Infection Predisposes to
TNF-Induced Liver Damage
(A) Intravenous challenge of H-2bmicewith OVA or
BSA (2 mg/mouse) ± TNF (1 mg/mouse) followed
by CTL transfer (107/mouse); sALT was measured
1 day later.
(B) Infection with AdOVA (2 3 108 pfu/mouse) or
UV-irradiated virus followed by TNF challenge
(400 ng/mouse) 2 days later; sALT at 4 hr.
(C) Systemic application of TLR, RIG-I, and AIM2
ligands followed by i.v. TNF-challenge and sALT
measurements at 4 hr. AdOVA-infected (5 3 108
pfu/mouse) and TNF-challenged mice served as
positive controls.
(D) Infection with increasing virus dose; TNF-
challenge and sALT determination as in (B).
(E an F) Viral infection (109 pfu/mouse) of mice;
sALT (E) and liver histology (F) at indicated time
points after TNF challenge. Scale bars, 200 mm.
(G and H) LCMV infection (104 pfu/mouse) fol-
lowed by TNF challenge 2 days later and (G) sALT
determination at 4 hr (n = 4 mice per group; one
out of five experiments is shown) or (H) determi-
nation of viremia at day 1 (n = 3 mice per group;
one out of two experiments is shown). **, signifi-
cant (p = 0.0011).
(I) WT or TNFR knockout mice were infected with
AdOVA as in Figure 1 and i.v. challenged 1 day
later with pIC (100 mg/mouse) followed by TNF and
sALT determination as above (n = 3 mice per
group; one out of three experiments is shown).
In (B)–(G), n = 4–5 mice per group; one out of three
representative experiments is shown.
See also Figure S3.TLR3 stimulation of infected mice amplified the ensuing TNF-
mediated liver damage (Figure 3I). Clearly, liver damage
depended on TNF even under these circumstances because
no effect was seen if poly-IC was applied alone or when mice
deficient for TNFR were employed (Figure 3I), indicating that
low-grade inflammation accentuates the effector function of
TNF in mediating viral hepatitis.Cell Reports 2, 478–487, SeTNFR Signaling in Infected
Hepatocytes Causes Cell Death
To test whether CTL-derived TNF acted
directly on hepatocytes, we employed
mice deficient in hepatocellular TNFR
signaling by hepatocyte-specific ablation
of FADD, an essential component of
the TNFR-signaling pathway (Ermolaeva
et al., 2008). These mice were protected
from TNF-induced liver damage after viral
infection (Figure 4A), which identified
hepatocytes as direct targets of TNF
and suggested selective TNF-induced
death in infected hepatocytes. Accord-
ingly, active caspase-3 was only de-
tected in hepatocytes of mice infected
with adenovirus or LCMV and challenged
with TNF, but not in mock-treated in-fected livers or upon TNF challenge alone (Figure 4B). Im-
portantly, cell death was observed exclusively in virus-infected
hepatocytes (Figure 4C). We did not observe collateral cell
death because TUNEL-positive hepatocytes were all in-
fected with adenovirus, whereas no uninfected hepatocytes
were TUNEL positive (Figure 4D). Because hepatocytes were
the direct target of TNF, these findings indicated that theptember 27, 2012 ª2012 The Authors 483
Figure 4. TNF Directly Targets Virus-
Infected Hepatocytes
(A) Adenoviral infection of transgenic mice bearing
a hepatocyte-specific FADD ablation (FADDfl/fl
xAPF-Crepos; control: FADDfl/fl xAPF-Creneg),
2 days later TNF challenge, and sALT after 4 hr.
(B and C) Mice were infected with adenovirus (53
108 pfu/mouse) or LCMV (1 3 102 pfu/mouse);
2 days later TNF challenge and 1 hr after TNF-
challenge liver immunohistochemistry for (B)
cleaved active caspase-3 (brown) and for (C) GFP
expression (brown) in combination with TUNEL
staining (red and black arrowheads).
(D) Quantification of TUNEL+ hepatocytes in
uninfected and adenovirus-infected mice (5 3
108pfu/mouse) (n = 4 mice per group; one out of
three experiments is shown).
(E and F) Immunoblot detecting caspase activa-
tion in hepatocytes isolated from livers of adeno-
virus-infected (E) or LCMV-infected (F) mice
treated as indicated.
(G and H) Treatment of adenovirus-infected (G) or
LCMV-infected mice (H) with a caspase inhibitor,
sALT 4 hr after TNF challenge (n = 4 mice per
group; one out of four independent experiments is
shown). *, significant (p = 0.0153) in (G). *, signifi-
cant (p = 0.0306) in (H).sensitization in infected hepatocytes observed in our experi-
ments resulted from cell-autonomous mechanisms. Because
we observed increased numbers of TUNEL-positive and active
caspase-3-positive hepatocytes in virus-infected livers, we
wondered whether caspase activation was involved in TNF-
induced death of infected hepatocytes. Western blotting con-
firmed this assumption, showing activated caspase-3 only
in virus-infected hepatocytes of mice challenged with TNF
(Figures 4E and 4F). Moreover, a pan-caspase inhibitor attenu-
ated TNF-induced viral hepatitis (Figures 4G and 4H). These
results demonstrated that CTLs activated by cross-presenting
LSECs killed specifically virus-infected hepatocytes through
TNF-induced apoptosis.484 Cell Reports 2, 478–487, September 27, 2012 ª2012 The AuthorsDISCUSSION
Viruses have evolved various strategies
to evade the immune response, which
include escape from CTL recognition
by downregulation of MHC I expres-
sion and prevention of classical MHC I-
restricted antigen presentation as well
as escape from innate immune response
by interfering with IFN signaling and
induction of apoptosis (Klenerman and
Hill, 2005; Rehermann and Nascimbeni,
2005). Cross-priming by DCs solves this
problem only partially by generating
sufficient numbers of CTLs in lymphatic
tissues (Kurts et al., 2010) because as
long as viral immune escape is opera-
tional in infected cells, activated CTLs
fail to recognize and kill their targets andremain ineffectual (Holtappels et al., 2004). Here, we report on
the discovery of a noncanonical CTL effector mechanism that
selectively kills virus-infected target cells in the absence of
MHC I-restricted target cell recognition and thereby com-
plements conventional CTL-mediated immune surveillance
effected through CD95L, perforin, and granzyme B.
It is believed that the key mechanism of immune surveillance
by CTLs is target cell killing upon recognition of peptide-loaded
MHC I molecules directly on the target cell. However, this MHC
I-restricted direct target cell recognition accounted for only
about 50%–60%of total CTL effector function in an experimental
model of viral hepatitis where only hepatocytes expressedMHC I
molecules. This raised the question by which mechanism the
remaining CTL effector function was achieved. We found that
cross-presentation of antigens derived from adenovirus-
infected hepatocytes by organ-resident LSECs to blood-borne
CTLs was sufficient to induce hepatitis even in the complete
absence of MHC class I-restricted antigen recognition on in-
fected hepatocytes. When we characterized the molecular
mechanisms by which LSEC cross-presentation to effector
CTLs led to hepatitis, we found a so far unrecognized CTL
effector function that depends on TNF. This was surprising
because we had previously shown that naive CTLs are rendered
nonresponsive when stimulated by cross-presenting LSECs
(Diehl et al., 2008; Limmer et al., 2000). Our present findings
demonstrate that the tolerogenic effect of LSECs is restricted
to stimulation of naive CTLs and does not compromise the
execution of CTL effector function, which allows these cells to
fulfill their function in peripheral immune surveillance. Our find-
ings also reveal that CTL immune surveillance can occur inde-
pendently from direct MHC-restricted target cell recognition,
which allows CTLs to control viral infection in the infected liver
more rapidly and efficiently.
Microvascular endothelial cells may contribute to CTL immune
surveillance also in other organs because endothelial cells of
the pancreas and the blood-brain barrier are capable of cross-
presentation and contribute to CTL transmigration into those
organs (Galea et al., 2007; Savinov et al., 2003). However,
in most studies reported, endothelial cells did not mediate
antigen-specific CTL activation but their attraction through
increased chemokine expression, e.g., following CD4 T cell acti-
vation by antigen-presenting DCs within infected tissue that
triggered local chemokine expression as shown in the genitouri-
nary tract (Nakanishi et al., 2009) or the kidney (Heymann et al.,
2009). Although we cannot exclude a role for chemokine-
mediated attraction of CTLs in amplification of viral hepatitis, the
antigen-specific activation of CTLs by cross-presenting LSECs
clearly was the initiating event for development of hepatitis.
Given the independence of target cell killing from direct MHC
class I recognition on target cells, we explored the pathogenic
role of soluble mediators involved in antiviral immunity and liver
damage during viral infection, such as TNF, type I and type II
IFNs (Guidotti and Chisari, 2001; Lang et al., 2006). Type II IFN
release from CTLs has been shown to contribute to control of
viral infection in hepatocytes (Giannandrea et al., 2009; Jo
et al., 2009). We identified TNF released from activated CTLs
as the only essential and sufficient factor thatmediates cell death
selectively in virus-infected hepatocytes. However, TNF re-
leased from macrophages, neutrophils, NK/T cells, or CD4+
T cells (Gao et al., 2009; Mosser and Edwards, 2008; Nathan,
2006) may further amplify the response initiated by CTLs that
were locally reactivated through cross-presentation. Because
the lack of TNF expression in CTLs caused a 40% reduction of
liver damage in infected mice with ubiquitous MHC I expression,
we conclude that the TNF-dependent effector function accounts
for a substantial portion of total CTL effector function even in the
presence of FAS-L, perforin, or granzyme B. This demonstrates
that CTL immune surveillance against viral infection involves two
distinct mechanisms, which both are MHC I restricted, but only
one requires direct MHC-restricted antigen recognition on target
cells, whereas the other relies on cross-presentation and TNF-Celmediated killing of target cells that does not require direct
MHC I recognition.
A role of TNF in noncytolytic control of viral replication but not
in mediation of hepatocyte death was observed in mice with
transgenic expression of viral antigens in hepatocytes (Guidotti
and Chisari, 2001). Our experiments clearly demonstrate that
TNF does not inflict damage to a noninfected liver but that it
causes hepatitis once viral infection sensitizes hepatocytes for
the death-inducing effects of TNFR signaling. TNF acted directly
on infected hepatocytes to induce cell death because mice with
hepatocyte-selective knockout of FADD, which constitutes an
important component of TNFR signaling (Ermolaeva et al.,
2008), did not develop TNF-dependent viral hepatitis. Because
FADD also contributes to FAS-mediated death (Peter and Kram-
mer, 2003), we cannot formally exclude an additional role for
FAS-L in noncanonical CTL effector function. However, liver
damage inflicted through anti-FAS antibody develops in nonin-
fected livers (Ogasawara et al., 1993), indicating that FAS death
receptor signaling does not discriminate between healthy and
infected hepatocytes. Death of virus-infected hepatocytes
following TNFR signaling involved caspase activation because
pharmacologic caspase inhibition alleviated hepatitis. Although
the molecular mechanisms determining the increased suscepti-
bility of infected hepatocytes to the proapoptotic effects of TNF
still need to be determined, our findings establish a robust exper-
imental system for future research on the differential outcome of
TNFR signaling in vivo.
This noncanonical CTL effector function may bear advantages
for antiviral immunity in situations such as (1) viral escape from
CTL and NK cell immune surveillance through expression of
MHC class I decoy molecules (Farrell et al., 1997), (2) viral
interference with IFN signaling or prevention of IFN induction in
the liver (Protzer et al., 2012; Rehermann and Nascimbeni,
2005), or (3) impaired sensing of viral infection by innate immune
receptors or by danger-sensing inflammasomes that prohibits
execution of programmed cell death in infected cells (Bowie
andUnterholzner, 2008;Schroder andTschopp, 2010).However,
impaired generation of sufficient numbers of antiviral CTLs may
compromise also the effect of the noncanonical effector function
because large CTL numbers are required for efficient pathogen-
specific immunity against infected hepatocytes (Protzer et al.,
2012). A further implication of our findings is that therapies aiming
at neutralizing TNF, for example in rheumatoid arthritis or colitis,
suppress such antiviral defense, which is suggested by recent
reports by Chung et al. (2009) and Li et al. (2009).
In summary, we report a noncanonical CTL effector function
that may not only overcome viral immune escape in infected
cells, which interferes with CTL recognition or innate immune
sensing in infected cells directly causing apoptosis. This nonca-
nonical CTL effector function may also accelerate and improve
local antiviral immune surveillance by complementing conven-
tional CTL-mediated elimination of virus-infected cells. It reveals
a novel principle of how innate immune sensing in infected target
cells supports cell death execution and attributes specificity to
death-inducing effector functions from adaptive immunity. The
identification of this noncanonical CTL effector function will aid
in the design of strategies for overcoming dysfunctional immune
responses in persistent viral infections.l Reports 2, 478–487, September 27, 2012 ª2012 The Authors 485
EXPERIMENTAL PROCEDURES
Determination of Liver Damage
sALT levels were determined with Reflotron test strips (GPT) with a Reflotron
analysis system from Roche Diagnostics (Mannheim, Germany) according to
the manufacturer’s instructions. Animal experiments were conducted after
approval of experimental protocols by local authorities and kept under stan-
dardized SPF-conditions in the central animal facility of the Medical Faculty
of the University of Bonn.
Viruses
Recombinant adenovirus expressing Ovalbumin, GFP, and Luciferase driven
by a CMV promoter (AdOVA) and adenovirus expressing GFP driven by
CMV promoters (AdGFP) were generated as described by Stabenow et al.
(2010). Recombinant adenoviral stocks were grown and purified as described
earlier by Sprinzl et al. (2001). Recombinant Ad-Virus was UV irradiated
50 mJ/cm2 for 2.5 min. LCMV strain WE was kindly provided by K. Lang.
Flow Cytometry
A total of 5 3 105 to 1 3 106 cells were stained with saturating concentrations
of antibodies plus 10 mg/ml Fc-block (clone 2.4G2) in FACS buffer (PBS/1%
bovine serum albumin, 2 mM EDTA/0.02%NaAz). Data acquisition and anal-
ysis were conducted on a FACS CantoII (BD Bioscience) using FlowJo soft-
ware (Tree Star, Ashland, OR, USA). To exclude dead cells, Hoechst 33258
(Sigma-Aldrich, Munich) was added at a final concentration of 1 mg/ml. TNF
concentration was measured using FlowCytomix Basic kit (BenderMed
Systems, Vienna) according to the manufacturer’s instructions.
Statistical Analysis
Student’s t test was used to determine statistical significance of results.
Results are shown as mean ± SD for representative experiments. The p values
<0.05 were considered significant: *<0.05, **<0.01, ***<0.001.
SUPPLEMENTAL INFORMATION
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10.1016/j.celrep.2012.08.001.
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